Study of TAS-102 plus apatinib for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two pills (TAS-102 and apatinib) as a third treatment option for people with advanced stomach cancer that has worsened after two prior treatments. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stomach cancer (confirmed by biopsy or other lab test).
- Your cancer cannot be removed with surgery or has spread to other parts of your body.
- You are between 18 and 75 years old.
- You are able to take care of yourself and carry out daily activities (ECOG score 0–2).
- You have already tried two previous treatments for advanced stomach cancer, and your cancer got worse during or after the second treatment.
- You have at least one tumor that can be measured with a scan (CT, MRI, etc.).
- Your blood counts and liver/kidney function are within safe limits (your doctor will check).
- You cannot be pregnant or plan to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of three drugs (adebrelimab, apatinib, and liposomal irinotecan) for people with advanced gastric or gastroesophageal junction cancer whose first treatment stopped working. The goal is to see if this new combination can help when standard options have failed.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This trial studies whether combining camrelizumab (an immunotherapy) and apatinib (a targeted pill) can control advanced, unresectable stomach or gastroesophageal junction cancer that has grown after first treatment. It also looks at how safe the combination is.
This trial tests a combination of three drugs to treat stomach or junction cancer that has spread or come back after initial immunotherapy treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding an immunotherapy drug (adebrelimab) with or without another targeted drug (apatinib) to standard chemotherapy is more effective for advanced stomach cancer. It aims to shrink tumors and improve outcomes for people who haven't had prior treatment for advanced disease.
Hear when a new Advanced Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.